Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature. Issue 8 (February 2017)

• Record Type: Journal Article
• Authors: Jia, Jinjing; Li, Wensheng; Zheng, Yan
• Other Names: Shu. Yi section editor.
• Is Part Of: Medicine. Volume 96:Issue 8(2017)
• Publication Date: 2017-02
• Subjects: B cell lymphoma -- diffuse large B cell lymphoma -- skin perforation -- R-CHOP chemotherapy; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000006161
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: The occurrence of primary cutaneous diffuse large B cell lymphoma-other (PCDLBCL-O) has been rarely reported in the literature. Its diagnosis is based on histopathological and immunohistochemical examinations. To improve the clinical diagnosis and treatment for PCDLBCL-O, we report a case of PCDLBCL-O successfully treated by the combination of R-CHOP (A chemotherapy protocol consists of cyclophosphamide, doxorubicin, vincristine, prednisone plus Rituximab) chemotherapy and surgery. The clinical manifestations, pathological characteristics, treatment and prognosis of the case were analyzed. Patient concerns: The patient was a 56-year-old female, presenting with red plaques and nodules in her left breast for 6 months. Diagnoses: Based on the clinical manifestation, histopathological and immunohistochemical results, the patient was diagnosed with PCDLBCL-O. Interventions: She was treated with 6 courses of R-CHOP chemotherapy combined with surgical resection. Outcomes: In the present case, fairly good curative effect was appeared with no recurrence within the 3 years' follow-up. Lessons: Primary cutaneous diffuse large B cell lymphoma commonly occurs on the legs (leg type), rarely on other sites of the body. The clinical manefestations are so variant that its diagnosis depends on histopathological and immunohistochemical examinations. Like systemic diffuse large B cell lymphoma, patients should be treated with systemic chemotherapy.